Moreover, serum SAA concentration was remarkably reduced by antirheumatic drugs in patients with RA, particularly by Tocilizumab, an inhibitor of potent SAA-inducing cytokine IL-6, correlating well with RA activity and treatment outcomes. Here, SAA2 is linked to rheumatoid arthritis.